1. Practical Guidance on the Management of Pan-Negative NSCLC

3. Overview

4. Evolution of NSCLC Subtyping From Histologic to Molecular Based

5. Case 1 Presentation

7. Selecting Therapy in a Newly Diagnosed Patient

8. Case 1 Presentation (cont)

9. Standard of Care for NSCLC Without Actionable Mutations

10. Does Extending Chemotherapy Improve Outcomes?

11. Phase 3 Trial: Cisplatin-Pemetrexed vs Cisplatin-Gemcitabine in Advanced NSCLC

12. Treatment Options for Squamous Cell NSCLC

13. Phase 3 Study Design

15. SQUIRE: Study Design

16. SQUIRE: Results

17. Case 1 Presentation (cont)

19. Maintenance Therapy

20. PointBreak: Phase 3 Trial of Pemetrexed or Paclitaxel Plus Carboplatin and Bevacizumab[a]

21. Case 2 Presentation

22. Case 2 Presentation (cont)

23. Treatment Options for Progressive or Recurrent NSCLC

24. REVEL: Study Design

25. REVEL: Results

27. AEs of Immunotherapies

28. Conclusions

29. Abbreviations

30. Abbreviations (cont)